When programmed death-ligand 1 (PD-L1)—a protein present on the surface of tumor cells—binds the PD-1, the signal is sent to suppress the immune system response; therefore, the inhibitors of PD-L1/PD-1 signaling pathway could be promising agents in cancer immunotherapy [141]. Here, CD274 is linked to cancer.